Newly minted AGC Biologics announces plans to expand manufacturing footprint

A bar chart showing positive business growth
AGC Biologics, a CDMO recently formed out of the integration of Asahi Glass Company Bioscience, Biomeva and CMC Biologics, plans to expand its headquarters in Bothell, Washington. (Getty/NicoElNino)

AGC Biologics, a CDMO recently formed out of the integration of Asahi Glass Company Bioscience, Biomeva and CMC Biologics, said it will expand its headquarters in Bothell, Washington.

The new 150,000-square-foot building complex will become part of the company’s current facility and will contain process development labs, corporate offices and room to expand AGC’s manufacturing capacity, the company said.

The addition is part of the company’s plans to expand its presence in the U.S. and will also include a R&D center for the development of new manufacturing technologies for faster development of therapeutic proteins.

The company didn’t disclose the projected cost of the project.

“We continue to demonstrate our dedication to sustained growth in order to support our customers’ increasing demand for both mammalian and microbial development and manufacturing services,” Gustavo Mahler, AGC’s president and CEO, said in a statement. “These new state-of-the-art facilities will enable us to meaningfully advance and further integrate the development, manufacturing, and commercial functions within our dynamic global headquarters, as well as provide additional footprint for further manufacturing expansion.”

AGC, which was formed and rebranded earlier this year, is focused on services for the scale-up and manufacturing of protein-based therapeutics.

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.